CCL24 and metabolic dysfunction-associated steatohepatitis: Additionally, in several animal models of NASH and liver fibrosis, CCL24 blockage by the anti-CCL24 monoclonal antibody, CM-101 (D8), significantly reduces liver damage, most importantly by directly reducing liver fibrosis (30).